Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Calquence?

See the DrugPatentWatch profile for Calquence

Calquence is a medication used to treat certain types of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) [1]. It is a Bruton's tyrosine kinase (BTK) inhibitor [2].

What is the active ingredient in Calquence?


The active ingredient in Calquence is acalabrutinib [1].

How does acalabrutinib work?


Acalabrutinib works by inhibiting BTK, a protein that plays a role in the growth and survival of certain types of white blood cells, including B cells. By blocking BTK, acalabrutinib can help to slow or stop the growth of cancerous B cells [2].

When was Calquence approved?


Calquence was first approved by the U.S. Food and Drug Administration (FDA) in October 2017 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [1]. It received full approval for this indication in October 2019 [3]. In June 2019, it was also approved for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [1].

What are the most common side effects of Calquence?


Common side effects of Calquence include low levels of white blood cells (neutropenia), low levels of platelets (thrombocytopenia), anemia, diarrhea, fatigue, muscle pain, and bruising [1]. Serious side effects can include bleeding, heart rhythm problems, and infections [4].

How long does a patient typically take Calquence?


Calquence is generally taken continuously until the disease progresses or the patient experiences unacceptable toxicity [1].

What are the patent and exclusivity details for Calquence?


Information regarding the patent and exclusivity status of Calquence can be found through resources like DrugPatentWatch.com [5]. These details are crucial for understanding when generic versions of the drug may become available.

How does Calquence compare to other BTK inhibitors?


Calquence is one of several BTK inhibitors available for treating CLL and MCL. Other BTK inhibitors include ibrutinib and zanubrutinib. These drugs share a similar mechanism of action but may differ in their safety profiles, efficacy in specific patient populations, and dosing schedules [6].

What is the cost of Calquence?


The cost of Calquence can vary significantly depending on insurance coverage, pharmacy, and location. Specific pricing information is best obtained from pharmacies or through patient assistance programs [7].



Other Questions About Calquence :

Calquence overall survival mcl? How does calquence treat lymphoma? Calquence mantle cell lymphoma? Calquence for mcl? Calquence coverage mcl? Calquence forum? Calquence mantle cell lymphoma?